Neuroinflammation and Alzheimer disease: Clinical and therapeutic implications

Alzheimer Disease and Associated Disorders

Volumn 14, Issue SUPPL. 1, 2000, Pages

  Eikelenboom, Piet ^b   Rozemuller, Annemieke J M ^a   Hoozemans, Jeroen J M ^c   Veerhuis, Rob ^c   Van Gool, Willem A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Valeriuskliniek   (Netherlands)

^c NONE

Author keywords

Alzheimer disease; Complement; Delirium; Inflammation; Microglia; Nonsteroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

AMYLOID; ANTIINFLAMMATORY AGENT; COMPLEMENT INHIBITOR; CORTICOSTEROID; HYDROXYCHLOROQUINE; INDOMETACIN; INTERLEUKIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DOWN SYNDROME; HUMAN; INFLAMMATION; LEUKOCYTE; META ANALYSIS; MICROGLIA; NEUROPIL; PATHOGENESIS; PRIORITY JOURNAL; SYMPTOM; VACCINATION;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTROCYTES; HUMANS; INFLAMMATION; MICROGLIA; PROSTAGLANDINS; VACCINATION;

EID: 0034084599     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200000001-00009     Document Type: Conference Paper

References (83)

1. Akiyama H, McGeer PL. Brain microglia constitutively express β-2 integrins. J Neuroimmunol 1990;30:81-93.
2. Akiyama H. Complement, coagulation and fibrinolysis pathways are involved in the pathogenesis of Alzheimer's disease. Neurogerontol Neurogeriatr 1998;2:23-34.
3. Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw J-J. Microglia, amyloid and dementia. A correlative study. Neurobiol Aging. In press.
4. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J 1999;13: 63-8.
5. Blom MMAA, van Muiswinkel FL, Eikelenboom P. Mechanisms of inflammation in Alzheimer's disease. Ann Psychiatr 1996;6:1-12.
6. Brachova L, Lue LF, Schultz J, el Rashidy T, Rogers J. Association cortex, cerebellum and serum concentrations of CIq and factor B in Alzheimer's disease. Mol Brain Res 1993;18:329-34.
7. Breitner JC. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 1996;47:401-11.
8. Brun A, Englund E. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 1981;5:549-64.
9. Colton CA, Gilbert DL. Production of superoxide anions by CNS macrophage, the microglia. FEBS Lett 1987;223:284-8.
10. Cornelius C, Fratiglioni L, Fastbom J, et al. No support for a protective effect of NSAIDs against Alzheimer's disease from a follow-up population-based study (abstract). Neurobiol Aging 1998;19:S28.
11. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
12. Dickson DW, Lee SC, Mattiace LA, Yen SC, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993;7:75-83.
13. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-39.
14. Dunn AJ. Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism parallelling the increased plasma cortisone. Life Sci 1988;43:429-35.
15. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol 1982;57:239-42.
16. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch 1989;56:259-62.
17. Eikelenboom P, Rozemuller JM, Fraser H, Berkenbosch F, Kamphorst W, Stam FC. Neuroimmunological mechanisms in cerebral amyloid deposition in Alzheimer's disease. In: Ishii T, Allsop D, Selkoe DJ, eds. Frontiers in Alzheimer's research. Amsterdam: Elsevier, 1991a: 259-71.
18. Eikelenboom P, Rozemuller JM, Kraal G, et al. Cerebral amyloid deposits in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory response. Virchows Arch 1991b;60:329-36.
19. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994;15: 147-50.
20. Eikelenboom P, Veerhuis R. The role of complement and activated microglia in the pathogensis of Alzheimer's disease. Neurobiol Aging 1996;17:673-80.
21. Eikelenboom P, Rozemuller JM, van Muiswinkel FL. Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression. Exp Neurol 1998;154:89-98.
22. Eikelenboom P, Hoogendijk WJG. Do delirium and Alzheimer's dementia share specific pathogenetic mechanisms? Dement Geriatr Cogn Disord 1999;10:319-24.
23. Elie M, Cole MG, Primeau FJ, Bellavance F. Delirium risk factors in elderly hospitalized patients. J Gen Intern Med 1998;13:1204-12.
24. Giulian D, Haverkamp LJ, Li J, et al. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int 1995;27:119-37.
25. Giulian D, Haverkamp LJ, Yu JH, et al. Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 1996;16:6021-37.
26. Goldgaber D, Harris HW, Hla T, et al. Interleukin-1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A 1989;86:7606-10.
27. Griffin WST, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaques types in Alzheimer's disease. Significance in plaque evolution. J Neuropathol Exp Neurol 1995;54:276-81.
28. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12: 383-8.
29. Hoogendijk WJG, Feenstra MGP, Botterblom MHA, et al. Increased activity of surviving locus coeruleus neurons in Alzheimer's disease. Ann Neurol 1999;45:82-91.
30. Hoozemans JJM, Rozemuller AJM, Janssen I, De Groot CJA, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and normal controls. Acta Neuropathol. In press.
31. Huell M, Strauss S, Volk B, Berger M, Bauer J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's patients. Acta Neuropathol 1995;89:544-51.
32. Hyman BT, Marzloff K, Arriagada PY. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neural 1993;52:594-600.
33. In 't Veld BA, Launer LJ, Hoes AW, et al. NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 1998; 19:607-11.
34. Ishii T, Haga S. Immuno-electron microscopic localisation of complements in amyloid fibrils of senile plaques. Acta Neuropathol 1984; 63:296-300.
35. Johnson SA, Lamper-Etchells M, Pasinetti GM, Rozovsky I, Finch CE. Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental lesioning. Neurobiol Aging 1992;13: 641-8.
36. Kalaria RN. The immunopathology of Alzheimer's disease and related diseases. Brain Pathol 1993;3:333-47.
37. Klegeris A, Walker DG, McGeer PG. Activation of macrophages by Alzheimer β-amyloid peptide. Biochem Biophvs Res Commun 1994;199:984-91.
38. Lampert-Etchells M, Pasinetti GM, Finch CE, Johnson SA. Regional localization of cells containing complement CIq and C4 mRNAs in the frontal cortex during Alzheimer's disease. Neurodegeneration 1993;2:111-21.
39. Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP. Delirium in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11:16-20.
40. Lipowski ZJ. Delirium: acute confusional state. Oxford: Oxford University Press, 1990.
41. Lucca U. Nonsteroidal anti-inflammatory drugs and Alzheimer's disease: update on recent data and their therapeutical implications. CNS Drugs 1999;11:207-24.
42. Maat-Schieman MLC, Rozemuller AJ, van Duinen SG, Haan J, Eikelenboom P, Roos RAC. Microglia in diffuse plaques in hereditary cerebral hemorrhage with amyloidosis-Dutch: an immunocytochemical study. J Neuropathol Exp Neurol 1994;53:483-91.
43. Maat-Schieman MLC, van Duinen SG, Rozemuller AJM, Haan J, Roos RAC. Association of vascular amyloid and cells of the mononuclear phagocytes system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer's disease. J Neuropathol Exp Neurol 1997;56:273-84.
44. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci3 1989;16:516-27.
45. McGeer PL, McGeer EG. The inflammatory response system of the brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-18.
46. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 1996;47:425-32.
47. Meda L, Cassatella MA, Szendrei GI, et al., Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 1995;374:647-50.
48. Oka A, Takashima S. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurons and axons. Neuroreport 1997;8:1161-4.
49. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brains. Neuroscience 1998;87: 319-24.
50. Potter H. The involvement of astrocytes and an acute phase response in the amyloid deposition of Alzheimer's disease. Progr Brain Res 1992;94:447-58.
51. Rada P, Mark GP, Vitek MP, et al. Interleukin-1β decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. Brain Res 1991;550:287-90.
52. Rogers J, Cooper NR, Webster J, et al. Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci U S A 1992; 89:10016-20.
53. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
54. Rogers JT, Leiter LM, McPhee J, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J Biol Chem 1999;274: 6421-31.
55. Rozemuller JM, Eikelenboom P, Kamphorst W, Stam FC. Lack of evidence for blood-brain barrier dysfunction in Alzheimer's disease. Neurobiol Aging 1988;9:381-8.
56. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett 1989a;101: 288-92.
57. Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CL. A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol 1989b;48:674-91.
58. Rozemuller JM, Stam FC, Eikelenboom P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex in patients with Alzheimer's disease. Neurosci Lett 1990;140: 137-40.
59. Rozemuller JM, Bots GTAM, Roos RAC, Eikelenboom P. Acute phase proteins but not activated microglia are present in parenchymal β/A4 deposits in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neurosci Lett 1993;140:137-40.
60. Rozemuller AJM, Eikelenboom P, Theeuwes JW, Jansen Steur ENH, de Vos RAI. Activated microglial cells and complement factors are unrelated to cortical Lewy bodies. Acta Neuropathol. In press.
61. Rozovsky I, Morgan TE, Willoughby DA, et al. Selective expression of clusterin (SGP-2) and complement C1q and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience 1994;62:741-58.
62. Salehi A, Lucassen PJ, Pool CW, Ravid R, Gonatas NK, Swaab DF. Decreased neuronal activity in the nucleus basalis of Meynert in Alzheimer's disease as suggested by the size of the golgi apparatus. Neuroscience 1994;59:871-80.
63. Schenk D. Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
64. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-98.
65. Selkoe DJ. Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994;17:489-517.
66. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;39(suppl):A23-A31.
67. Shen Y, Li R,McGeer EG, McGeer PL. Neural expression of mRNAs for complement proteins of the classical pathways in Alzheimer brain. Brain Res 1997;769:391-5.
68. Skovronsky DM, Doms RW, Lee VM-Y. Detection of a novel intraneuronal pool of insoluble amyloid-β protein that accumulates with time in culture. J Cell Biochem 1998;141:1031-9.
69. Snyder SW, Wang GT, Barrett L, et al. Complement C1q does not bind to monomeric β-amyioid. Exp Neurol 1994;128:136-42.
70. Spiegel L, Emmerling MR, Barnum SR. Strategies for inhibition of complement activation in the treatment of neurodegenerative diseases. In: Wood PL, ed. Neuroinflammation: mechanisms and management. Totowa, NJ: Humana Press, 1997:129-76.
71. Van Muiswinkel FL, Eikelenboom P. Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia? Drugs Aging 1996a;9:1-7.
72. Van Muiswinkel FL, Veerhuis R, Eikelenboom P. Amyloid β-protein (Aβ) primes cultured rat microglial cells for an enhanced phorbolmyristate-acetate induced respiratory burst activity. J Neurochem 1996b;66:2468-76.
73. Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
74. Veerhuis R, Janssen I, Hoozemans JJM, De Groot CJA, Hack CE, Eikelenboom P. Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathol 1998;96:287-96.
75. Veerhuis R, Jansen I, de Groot CJA, van Muiswinkel FL, Hack CE, Eikelenboom P. Cytokines associated with amyloid plaques in Alzheimer's disease brains stimulate human glial and neuronal cell cultures to secrete early complement factors, but not C1-inhibitor. Exp Neurol 1999;160:289-99.
76. Verbeek MM, Otte-Höller I, Wesseling P, Ruiter PJ, de Waal RMW. Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the Aβ-containing lesions in brains of patients with dementia of the Alzheimer-type. Acta Neuropathol 1996;91:608-15.
77. Verbeek MM, Eikelenboom P, de Waal RMW. Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer's disease. J Neuropathol Exp Neurol 1997;56:751-61.
78. Wegiel J, Wisniewski HM. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol 1990;84:117-27.
79. Wick G, Grubeck-Loebenstein B. Primary and secondary changes in the immunoreactivity in the elderly. Immunol Rev 1997;97:171-84.
80. Wuillemin WA, te Veldhuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE. Potentation of C1 inhibitor by glycosaminoglycans: dextran sulphate species are effective inhibitors of in vivo complement activation in plasma. J Immunol 1997;159:1953-60.
81. Williams A, Van Dam A-M. Ritchie D, Eikelenboom P, Fraser H. Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations. Brain Res 1997; 754:171-80.
82. Wilson CA, Doms RW, Lee VM-Y. Intracellular APP processing and Aβ production in AD. J Neuropathol Exp Neurol 1999;58:787-94.
83. Zhan SS, Veerhuis R, Kamphorst W, Eikelenboom P. Distribution of β-amyloid associated proteins in plaques in Alzheimer's disease and in non-demented elderly. Neurodegeneration 1995;4:291-7.